Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 611-617

  Pressler, Tacjana ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cystic fibrosis; Lung disease; Recombinant human deoxyribonuclease

Indexed keywords

EID: 80053045351     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3052     Document Type: Review

References (62)

1. Aitken ML, Burke W, McDonald G, et al. 1992. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA, 267:1947-51.
2. Armstrong DS, Grimwood K, Carlin JB, et al. 1997. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med, 156:1197-204.
3. Armstrong DS, Grimwood K, Carzino R, et al. 1995. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ, 310:1571-2.
4. Armstrong DS, Hook SM, Jamsen KM, et al. 2005. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol, 40:500-10.
5. Balough K, McCubbin M, Weinberger M, et al. 1995. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol, 20:63-70.
6. Berge MT, Wiel E, Tiddens HA, et al. 2003. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros, 2:183-8.
7. Boe J, Dennis JH, O'Driscoll BR, et al. 2001. European Respiratory Society Guidelines on the use of nebulizers: Guidelines prepared by a European Respiratory Society Task Force on the use of nebulizers. Eur Respir J, 18:228-42.
8. Bollert FGE, Paton JY, Marshall TG, et al. 1999. Recombinant DNase in cystic fibrosis: A protocol for targeted introduction through n-of-1 trials. Eur Respir J, 13:107-13.
9. Chen B, Costantino HR, Liu JT, et al. 1999. Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states. J Pharm Sci, 88:477-82.
10. Chernick W 1959. Comparison of tracheobronchial secretion in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics, 24:739-45.
11. Chernick WS, Barbero GJ, Eichel HJ 1961. Invitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics, 27:589-96.
12. Cobos N, Danes I, Gartner S, et al. 2000. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Eur J Pediatr, 159:176-81.
13. Collins FS 1992. Cystic fibrosis: molecular biology and therapeutic implications. Science, 256:774-9.
14. Cystic Fibrosis Foundation. 2006. Patient Registry Annual Report.
15. Davies J, Trindade MT, Wallis C, et al. 1997. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol, 23:243-8.
16. Doring G, Høiby N 2004. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros, 3:67-91.
17. Eisenberg JD, Aitken ML, Dorkin HL, et al. 1997. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr, 131:118-24.
18. Fiel SB, Fuchs HJ, Johnson C, et al. 1995. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group. Chest, 108:153-6.
19. Frederiksen B, Pressler T, Hansen A, et al. 2006. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr, 95:1070-4.
20. Fuchs HJ, Borowitz DS, Christiansen DH, et al. 1994. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med, 331:637-42.
21. Harms HK, Matouk E, Tournier G, et al. 1998. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group. Pediatr Pulmonol, 26:155-61.
22. Hodson ME, McKenzie S, Harms HK, et al. 2003. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol, 36:427-32.
23. Houtmeyers E, Gosselink R, Gayan-Ramirez G, et al. 1999. Effects of drugs on mucus clearance. Eur Respir J, 14:452-67.
24. Hubbard R, McElvaney NG, Birrer P, et al. 1992. A preliminary study of aerosolised recombinant human deoxyribonuclease in treatment of cystic fibrosis. N Engl J Med, 326:812-5.
25. Jones AP, Wallis CE 2003. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev, (3):CD001127.
26. Khan TZ, Wagener JS, Bost T, et al. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med, 151:1075-82.
27. Kirchner KK, Wagener JS, Khan TZ, et al. 1996. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med, 154:1426-9.
28. Koch C, Høiby N 1993. Pathogenesis of cystic fibrosis. Lancet, 341(8852):1065-69.
29. Konstan MW, Hilliard KA, Norvell TM, et al. 1994. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med, 150:448-54.
30. Konstan MW, Morgan WJ, Butler SM, et al. 2007. Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis. J Pediatr, 151:134-9. e1.
31. Lieberman J. 1968. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA, 205:312-3.
32. McCoy K, Hamilton S, Johnson C, et al. 1996. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest, 110:889-95.
33. McKenzie SG, Chowdhury S, Strandvik B, et al. 2007. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol, 42:928-37.
34. Nasr SZ, Kuhns LR, Brown RW, et al. 2001. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol, 31:377-82.
35. Paul K, Rietschel E, Ballmann M, et al. 2004. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med, 169:719-25.
36. Perks B, Shute JK 2000. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics. Am J Respir Crit Care Med, 162:1767-72.
37. Petersen NT, Høiby N, Mordhorst CH, et al. 1981. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand, 70:623-8.
38. Potter JL, Spector S, Matthews LW, et al. 1969. Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis, 99:909-16.
39. Quan JM, Tiddens HA, Sy JP, et al. 2001. A two-year randomized, placebocontrolled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr, 139:813-20.
40. Ramsey BW, Astley SJ, Aitken ML, et al. 1993. Efficacy and safety of shortterm administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis, 148:145-51.
41. Ranasinha C, Assoufi B, Shak S, et al. 1993. Efficacy and safety of shortterm administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet, 342:199-202.
42. Ratjen F, Hartog CM, Paul K, et al. 2002. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax, 57:930-4.
43. Ratjen F, Paul K, van Koningsbruggen S, et al. 2005. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: Influence of treatment with dornase alpha. Pediatr Pulmonol, 39:1-4.
44. Riordan JR 2008. CFTR Function and Prospects for Therapy. Annu Rev Biochem, 77:701-26.
45. Riordan JR, Rommens JM, Kerem B, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245:1066-73.
46. Robinson M, Hemming AL, Regnis JA, et al. 1997. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax, 52:900-3.
47. Rommens JM, Iannuzzi MC, Kerem B, et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science, 245:1059-65.
48. Rosenfeld M, Gibson RL, McNamara S, et al. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol, 32:356-66.
49. Sagel SD, Kapsner R, Osberg I, et al. 2001. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med, 164:1425-31.
50. Sanders NN, Franckx H, De Boeck K, et al. 2006. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax, 61:962-8.
51. Shah PL, Conway S, Scott SF, et al. 2001. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration, 68:160-4.
52. Shah PL, Scott SF, Geddes DM, et al. 1997. An evaluation of two aerosol delivery systems for rhDNase. Eur Respir J, 10:1261-6.
53. Shah PL, Scott SF, Geddes DM, et al. 1995. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med, 89:499-502.
54. Shah PL, Scott SF, Knight RA, et al. 1996. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J, 9:531-4.
55. Shak S, Capon DJ, Hellmiss R, et al. 1990. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A, 87:9188-92.
56. Smith AL, Redding G, Doershuk C, et al. 1988. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr, 112:547-54.
57. Suri R, Marshall LJ, Wallis C, et al. 2002. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med, 166:352-5.
58. ten Berge M, van der Wiel E, Tiddens HAWM, et al. 2003. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros, 2:183-8.
59. van der Giessen LJ, de Jongste JC, Gosselink R, et al. 2007. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology, 42:624-30.
60. Wagener JS, Rock MJ, McCubbin MM, et al. 1998. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group. J Pediatr, 133:486-91.
61. Wilson CJ, Robbins LJ, Murphy JM, et al. 2007. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatr Pulmonol, 42:1110-6.
62. Zuelzer WW, Newton WA 1949. The pathogenesis of fibrocystic disease of the pancreas. A study of 36 cases with special reference to the pulmonary lesions. Pediatrics, 4:53-69.